Common use of Publicity; Use of Names Clause in Contracts

Publicity; Use of Names. The Parties agree that the public announcements by the Parties of the execution of this Agreement shall be substantially in the form of the press release or releases attached as Exhibit D and shall the Parties cooperate in the issuance thereof as soon as practicable after the Effective Date unless otherwise agreed by the Parties. In addition, the Parties recognize that each Party may from time to time desire to issue additional press releases and make other public statements or disclosures regarding this Agreement or activities conducted hereunder and that such press releases, statements or disclosures may be issued upon prior written approval of the other Party, such approval not to be unreasonably withheld or delayed. The disclosing Party shall provide the other Party a copy of any such proposed disclosures at least [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ten (10) Business Days prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such disclosing Party under Applicable Law or the rules of any internationally recognized stock exchange. Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party; provided however, that nothing herein shall prohibit the use of the trademark or trade name of a Product.

Appears in 2 contracts

Samples: Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD), Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD)

AutoNDA by SimpleDocs

Publicity; Use of Names. The Parties agree that the public announcements by the Parties of the execution of this Agreement shall be substantially in the form of the press release or releases attached as Exhibit D and shall the Parties cooperate in the issuance thereof as soon as practicable after the Effective Date unless otherwise agreed by the Parties. In addition, the Parties recognize that each Party may from time to time desire to issue additional press releases and make other public statements or disclosures regarding this Agreement or activities conducted hereunder and that such press releases, statements or disclosures may be issued upon prior written approval of the other Party, such approval not to be unreasonably withheld or delayed. The disclosing Party shall provide the other Party a copy of any such proposed disclosures at least [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ten (10) Business Days prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such disclosing Party under Applicable Law or the rules of any internationally recognized stock exchange. Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party; provided however, that nothing herein shall prohibit the use of the trademark or trade name of a Product.

Appears in 2 contracts

Samples: Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD), Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD)

Publicity; Use of Names. (a) The Parties agree that the public announcements by the Parties of shall issue a mutually acceptable press release announcing the execution of this Agreement shall be substantially in the form of the Agreement. A Party may issue any subsequent press release or releases attached as Exhibit D and shall the Parties cooperate in the issuance thereof as soon as practicable after the Effective Date unless otherwise agreed by the Parties. In addition, the Parties recognize that each Party may from time relating to time desire to issue additional press releases and make other public statements or disclosures regarding this Agreement or activities conducted hereunder and that such press releases, statements or disclosures may be issued upon prior written approval of the other Party, such approval not to be unreasonably withheld or delayed; provided, however, that no approval of the other Party shall be required if a subsequent press release solely discloses the information that: (1) a milestone under this Agreement has been achieved and/or any payments associated therewith have been received; (2) the filing and/or approval of the NDA with the FDA or the EMEA generally has occurred (provided, however, that specific dates of filing shall not be disclosed); (3) commercial launch of the Product in any country or any information that has previously been approved and disclosed as permitted by this Section 9.2. The In the case of items (1)-(3) of the preceding sentence, the disclosing Party shall provide the other Party a copy of any such proposed disclosures at least [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ten (10) Business Days prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such disclosing Party under Applicable Law applicable laws, rules or the rules of any internationally recognized stock exchangeregulations, including without limitation, applicable securities law. Neither Except as otherwise provided in this Section 9.2(a), neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party; provided however, that nothing herein shall prohibit the use of the trademark or trade name of a Product.

Appears in 1 contract

Samples: Exclusive License Agreement (Edesa Biotech, Inc.)

Publicity; Use of Names. The Parties agree that the public announcements by the Parties No disclosure of the execution of existence of, or the terms of, this Agreement shall be substantially in the form of the press release or releases attached as Exhibit D and shall the Parties cooperate in the issuance thereof as soon as practicable after the Effective Date unless otherwise agreed by the Parties. In addition, the Parties recognize that each Party may from time to time desire to issue additional press releases and make other public statements or disclosures regarding this Agreement or activities conducted hereunder and that such press releases, statements or disclosures AGREEMENT may be issued upon prior written approval of the other made by either Party, such approval not to be unreasonably withheld or delayed. The disclosing Party shall provide the other Party a copy of any such proposed disclosures at least [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ten (10) Business Days prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such disclosing Party under Applicable Law or the rules of any internationally recognized stock exchange. Neither Party no party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or publicity, news release or disclosure relating to this Agreement AGREEMENT or its subject matter, without the prior express written permission of the other Party, except as may be required by law. The parties acknowledge and agree that, upon and following the Effective Date, one or both of the Parties intends to issue a press release announcing the execution of this Agreement. The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of such press releases prior to the issuance thereof; provided provided, however, that nothing herein neither Party shall prohibit issue any such press releases without the use other Party's consent, which may not be unreasonably withheld. Either Party may issue such press releases or otherwise make such public statements or disclosures (such as in annual reports to stockholders or filings with the Securities and Exchange Commission) as it determines, based on advice of counsel, are reasonably necessary to comply with applicable laws and regulations; provided, however, that a Party shall not issue any such press releases or make such statements or disclosures without the other Party's prior review and comment. In addition, following any initial press release(s) announcing this Agreement or other public disclosure approved by both Parties, either Party shall be free to disclose, without the other Party's prior written consent, the existence of this Agreement, the identity of the trademark or trade name other Party and those terms of a Productthe Agreement which have already been publicly disclosed in accordance herewith.

Appears in 1 contract

Samples: Supply Agreement (Nastech Pharmaceutical Co Inc)

Publicity; Use of Names. The Parties intend to agree that upon the public announcements by content of one (1) or more press releases, the release of which the Parties of the shall coordinate in order to accomplish such release promptly upon execution of this Agreement shall be substantially Agreement. Other than as set forth in the form prior sentence, no other disclosure of the press release existence, or releases attached as Exhibit D and shall the Parties cooperate in the issuance thereof as soon as practicable after the Effective Date unless otherwise agreed by the Parties. In additionterms, the Parties recognize that each Party may from time to time desire to issue additional press releases and make other public statements or disclosures regarding of this Agreement or activities conducted hereunder and that such press releases, statements or disclosures may be issued upon prior written approval of the other Party, such approval not to be unreasonably withheld made by either Party or delayed. The disclosing Party shall provide the other Party a copy of any such proposed disclosures at least [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ten (10) Business Days prior to the proposed release and consider in good faith any comments the other Party may make, where practicableits Affiliates, and in light of any reporting obligations of such disclosing Party under Applicable Law or the rules of any internationally recognized stock exchange. Neither neither Party shall use the name, trademark, trade name or logo of the other Party Party, its Affiliates or its employees their respective employee(s) in any publicity or publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING, INC. IF PUBLICLY DISCLOSED. permission of the other Party; provided however, except as may be required by Applicable Laws. Notwithstanding the above, each Party and its Affiliates may disclose on its website, in news releases, its promotional materials and other disclosures relating to this Agreement that nothing herein shall prohibit the other Party is a development and commercialization partner of such Party for the Licensed Product in the Territory and may use of the trademark or trade other Party’s name of a Product.and logo in conjunction with such disclosure. Notwithstanding the foregoing:

Appears in 1 contract

Samples: License and Collaboration Agreement (VistaGen Therapeutics, Inc.)

AutoNDA by SimpleDocs

Publicity; Use of Names. (a) The Parties agree that the public announcements by the Parties of shall issue a mutually acceptable press release announcing the execution of this Agreement shall be substantially in the form of the Agreement. A Party may issue any subsequent press release or releases attached as Exhibit D and shall the Parties cooperate in the issuance thereof as soon as practicable after the Effective Date unless otherwise agreed by the Parties. In addition, the Parties recognize that each Party may from time relating to time desire to issue additional press releases and make other public statements or disclosures regarding this Agreement or activities conducted hereunder and that such press releases, statements or disclosures may be issued upon prior written approval of the other Party, such approval not to be unreasonably withheld or delayed; provided, however, that no approval of the other Party shall be required if a subsequent press release solely discloses the information that: (I) a milestone under this Agreement has been achieved and/or any payments associated therewith have been received; (2) the filing and/or Regulatory Approval of the NDA with the FDA or the EMEA generally has occurred (provided, however, that specific dates of filing shall not be disclosed); (3) commercial launch of the Product in any country or any information that has previously been approved and disclosed as permitted by this Section 8.2. The In the case of items (1 )-(3) of the preceding sentence, the disclosing Party shall provide the other Party a copy of any such proposed disclosures at least [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ten (10) Business Days prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such disclosing Party under Applicable Law applicable laws, rules or the rules of any internationally recognized stock exchange. Neither regulations, including applicable securities law, Except as otherwise provided in this Section 8.2(a), neither Party shall use the name, trademark, trade name or logo of the other Party or its employees employees, or, in the case of YISSUM, the name or logo of the University or the name of its employees, in any publicity or news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party; provided however, that nothing herein shall prohibit the use of the trademark or trade name of a Product.,

Appears in 1 contract

Samples: Exclusive License Agreement (Edesa Biotech, Inc.)

Publicity; Use of Names. The Parties agree that the public announcements by the Parties No disclosure of the execution of existence of, or the terms of, this Agreement shall be substantially in the form of the press release or releases attached as Exhibit D and shall the Parties cooperate in the issuance thereof as soon as practicable after the Effective Date unless otherwise agreed by the Parties. In addition, the Parties recognize that each Party may from time to time desire to issue additional press releases and make other public statements or disclosures regarding this Agreement or activities conducted hereunder and that such press releases, statements or disclosures may be issued upon prior written approval of the other made by either Party, such approval not to be unreasonably withheld or delayed. The disclosing Party shall provide the other Party a copy of any such proposed disclosures at least [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ten (10) Business Days prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such disclosing Party under Applicable Law or the rules of any internationally recognized stock exchange. Neither no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or publicity, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by law. The Parties acknowledge and agree that, upon and following the Effective Date, one or both of the Parties intends to issue a press release announcing the execution of this Agreement. The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of such press releases prior to the issuance thereof; provided provided, however, that nothing herein neither Party shall prohibit issue any such press releases without the use other Party's consent, which may not be unreasonably withheld. Either Party may issue such press releases or otherwise make such public statements or disclosures (such as in annual reports to stockholders or filings with the Securities and Exchange Commission) as it determines, based on advice of counsel, are reasonably necessary to comply with applicable laws and regulations; provided, however, that a Party shall not issue any such press releases or make such statements or disclosures without the other Party's prior review and comment. In addition, following any initial press release(s) announcing this Agreement or other public disclosure approved by both Parties, either Party shall be free to disclose, without the other Party's prior written consent, the existence of this Agreement, the identity of the trademark or trade name other Party and those terms of a Productthe Agreement which have already been publicly disclosed in accordance herewith.

Appears in 1 contract

Samples: And License Agreement (Nastech Pharmaceutical Co Inc)

Time is Money Join Law Insider Premium to draft better contracts faster.